Fig. 6.

Evaluation of the comparative lethality of Albuleukin and rIL-2 in the B16F10 melanoma model. Mice (n=12 per dose group) were injected with B16F10 melanoma and 3 days later with a 2-week regimen of Albuleukin or rIL-2 administered s.c. Doses of Albuleukin ranged from 0 to 4.0 mg/kg every 48 h. Doses of rIL-2 ranged from 0 to 5.0 mg/kg daily (doses were divided into two doses 8 h apart). Survival of each group at the conclusion of the 14-day treatment interval is shown. The dose of Albuleukin and rIL-2 selected for further evaluation was approximated between a dose that induced any lethality and the next lower, non-lethal, dose. This dose was about 1.75 mg/kg every other day for Albuleukin and 1.0 mg/kg/day kg (divided into two injections 8 h apart) for rIL-2. BID—twice a day, QOD—every other day. a Albuleukin. b rIL-2